Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Pfizer's internal candidate flamed out, and it's now making aggressive moves to re-enter the GLP-1 race. 10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often happens, the excitement on Wall Street overstated the opportunity. At this point, the stock has lost over two-thirds of its value since mid-2024. Could high-yield Pfizer (NYSE: PFE) be a better investment opportunity? Finding new drug candidates is hard and expensive. Developing and testing a promising candidate is hard and expensive. Navigating the regulatory process to bring a promising candidate to market is hard and expensive. Throughout the entire process, companies are in a race with other pharmaceutical companies to be the first to market with novel treatments. However, simply being first in a space doesn't guarantee a win.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market [Yahoo! Finance]Yahoo! Finance
- American Heart Association (AHA) Scientific Sessions Highlights Report 2025: Market Opportunities Lie in Novel Therapeutics Like Semaglutide, VK2735, SHR-1918, BacNav, and Satralizumab [Yahoo! Finance]Yahoo! Finance
- Is Novo Nordisk Now Attractive After a 48.8% Slide and DCF Reassessment? [Yahoo! Finance]Yahoo! Finance
- While the price of 15 prescription drugs is set to drop, only 5.3M Americans will benefit. Here's what you need to know [Yahoo! Finance]Yahoo! Finance
- ?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website